SIGA TECHNOLOGIES INC (SIGA)

Company Profile

SIGA Technologies, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company is headquartered in New York City, New York and currently employs 45 full-time employees. Health security comprises countermeasures for biological, chemical, radiological and nuclear attacks, vaccines and therapies for emerging infectious diseases, and health preparedness. The firm's lead product is TPOXX, also known as tecovirimat and ST-246, an orally administered and intravenous (IV) formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. TPOXX is a novel small-molecule drug and the United States maintains a supply of TPOXX under Project BioShield. The European Medicines Agency and United Kingdom approvals include labeling for oral tecovirimat indicating its use for the treatment of smallpox, monkeypox, cowpox, and vaccinia complications following vaccination against smallpox. The company uses third parties known as contract manufacturing organizations to procure commercial raw materials and supplies, and to manufacture TPOXX.

Company Info

SIGA TECHNOLOGIES INC

31 East 62Nd Street

New York City NEW YORK 10065

P: 12126729100

CEO: Phillip L. Gomez

Employees: 45

Website: https://www.siga.com/